Nevertheless, our study: (1) revealed the regulatory mechanism of IGF2BP3 expression as well as the cause of its abnormal expression; (2) confirmed that IGF2BP3 can promote bladder cancer development as well as revealed its molecular mechanism; (3) revealed molecular mechanism by which IGF2BP3 regulates the expression of HMGB1; and (4) demonstrated that IGF2BP3-HMGB1 can serve as a bladder cancer therapeutic target and the potential of glycyrrhizin as a therapeutic agent for bladder cancer. Here, HMGB1 is linked to urinary bladder carcinoma.